Clinical Trial Update: A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors [Phase 1]

View source ↗

Summary

A completed Phase 1 study evaluating the safety and tolerability of systemic gene therapy SGT-94 in patients with solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• SGT-94

Snippet

Sponsor: SynerGene Therapeutics, Inc. | Conditions: Neoplasm | Phase 1 | Status: COMPLETED